Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	6 Months Ended
	Jun. 29, 2019	Jun. 30, 2018
Cash Flows From (For) Operating Activities
Net income	$ 72.9	$ 117.0
Adjustments to derive cash flows:
Depreciation and amortization	191.5	217.8
Share-based compensation	28.0	22.3
Impairment charges	31.9	1.7
Change in financial assets	(15.9)	9.0
Loss on extinguishment of debt	0.0	0.5
Restructuring charges	21.5	5.2
Deferred income taxes	9.2	(14.2)
Amortization of debt premium	(3.0)	(3.7)
Other non-cash adjustments, net	26.4	5.1
Subtotal	362.5	360.7
Increase (decrease) in cash due to:
Accounts receivable	(55.3)	(24.3)
Inventories	(78.3)	(99.3)
Accounts payable	41.2	89.2
Payroll and related taxes	(23.0)	(48.4)
Accrued customer programs	(52.8)	33.9
Accrued liabilities	(19.2)	(30.4)
Accrued income taxes	(36.7)	(20.8)
Other, net	19.9	(5.9)
Subtotal	(204.2)	(106.0)
Net cash from (for) operating activities	158.3	254.7
Cash Flows From (For) Investing Activities
Proceeds from royalty rights	1.7	10.3
Purchase of investment securities		(7.5)
Royalty Pharma contingent milestone payment	250.0
Asset acquisitions	(35.0)
Additions to property, plant and equipment	(54.7)	(33.3)
Net proceeds from sale of business and other assets		1.3
Net cash from (for) investing activities	162.0	(29.2)
Cash Flows From (For) Financing Activities
Issuances of long-term debt		431.0
Payments on long-term debt	(158.9)	(457.3)
Borrowings (repayments) of revolving credit agreements and other financing, net	397.5	(8.2)
Deferred financing fees		(2.4)
Issuance of ordinary shares	0.3
Repurchase of ordinary shares		(265.0)
Cash dividends	(54.8)	(52.8)
Other financing, net	(5.9)	(7.5)
Net cash from (for) financing activities	178.2	(362.2)
Effect of exchange rate changes on cash and cash equivalents	6.1	(15.5)
Net increase (decrease) in cash and cash equivalents	504.6	(152.2)
Cash and cash equivalents, beginning of period	551.1	678.7
Cash and cash equivalents, end of period	$ 1,055.7	$ 526.5